Drug Description in Trials / DrugBank / KEGG DRUG
Search results
| No. | Drug (Description in trials) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | Disease ID |
|---|---|---|---|---|---|---|
| 1 | ALX-0081 | - | - | - | - | [1] 64 64 |
| 2 | Caplacizumab (ALX-0081) | [1] Caplacizumab Caplacizumab | [1] D11160
D11160
| [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |
| 3 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | [2] Caplacizumab Caplacizumab,Von Willebrand factor human | [1] D11160
D11160
| [1] VWF VWF 💬 | [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 |